Compare Stocks: AGIO, IMVT, IONS, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.20 -2.9%	$34.07	$22.24 ▼ $46.00	$1.99B	0.6	1.03 million shs	133,707 shs
ALKS Alkermes	$41.76 -0.9%	$48.46	$26.99 ▼ $55.67	$7.01B	0.31	2.13 million shs	172,150 shs
IMVT Immunovant	$34.15 -1.1%	$39.99	$15.22 ▼ $45.42	$7.05B	0.81	1.51 million shs	136,993 shs
IONS Ionis Pharmaceuticals	$44.26 +0.8%	$55.33	$43.01 ▼ $86.74	$7.34B	0.42	2.59 million shs	262,345 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.23%	+3.76%	+4.75%	-5.55%	-9.72%
ALKS Alkermes	-2.68%	-8.55%	-13.79%	-20.25%	+51.82%
IMVT Immunovant	-7.37%	-5.06%	-20.27%	-9.68%	+131.81%
IONS Ionis Pharmaceuticals	-3.98%	-2.03%	-29.19%	-43.92%	-29.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$33.20 -2.9%	$34.07	$22.24 ▼ $46.00	$1.99B	0.6	1.03 million shs	133,707 shs
ALKS Alkermes	$41.76 -0.9%	$48.46	$26.99 ▼ $55.67	$7.01B	0.31	2.13 million shs	172,150 shs
IMVT Immunovant	$34.15 -1.1%	$39.99	$15.22 ▼ $45.42	$7.05B	0.81	1.51 million shs	136,993 shs
IONS Ionis Pharmaceuticals	$44.26 +0.8%	$55.33	$43.01 ▼ $86.74	$7.34B	0.42	2.59 million shs	262,345 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.23%	+3.76%	+4.75%	-5.55%	-9.72%
ALKS Alkermes	-2.68%	-8.55%	-13.79%	-20.25%	+51.82%
IMVT Immunovant	-7.37%	-5.06%	-20.27%	-9.68%	+131.81%
IONS Ionis Pharmaceuticals	-3.98%	-2.03%	-29.19%	-43.92%	-29.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.75	22.11% Upside
ALKS Alkermes	2.78	Moderate Buy	$54.47	29.29% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	27.39% Upside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	103.05% Upside

Current Analyst Ratings Breakdown

Latest AGIO, IMVT, IONS, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$50.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/23/2026	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $61.00
9/22/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$76.00 ➝ $70.00
9/21/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/21/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/21/2026	ALKS Alkermes	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/21/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $50.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	37.78	N/A	N/A	$20.46 per share	1.67
ALKS Alkermes	$1.48B	4.79	$1.63 per share	25.85	$11.02 per share	3.82
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IONS Ionis Pharmaceuticals	$944M	7.73	N/A	N/A	$3.02 per share	14.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
ALKS Alkermes	$241.66M	$0.38	110.87	175.54	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)

Latest AGIO, IMVT, IONS, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
IONS Ionis Pharmaceuticals	3.07	7.89	7.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
IONS Ionis Pharmaceuticals	1.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable

AGIO, IMVT, IONS, and ALKS Headlines

Recent News About These Companies

Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright

2 hours ago | marketbeat.com

Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study

September 23 at 8:05 PM | finance.yahoo.com

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23 at 3:04 PM | rutlandherald.comR

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

September 23 at 1:16 PM | zacks.com

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

September 23 at 8:13 AM | benzinga.com

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23 at 1:00 AM | businesswire.com

Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results

September 22 at 3:51 PM | blockonomi.com

Ionis drug ulefnersen meets primary endpoint in FUS-ALS Phase 3 trial

September 22 at 9:58 AM | streetinsider.com

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

September 22 at 9:58 AM | marketscreener.comM

JPMorgan Chase & Co. Issues Pessimistic Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price

September 22 at 8:41 AM | marketbeat.com

Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study

September 22 at 8:37 AM | reuters.com

Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 12-Month Low - Time to Sell?

September 21 at 11:19 AM | marketbeat.com

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook

September 20, 2026 | fool.com

Bank of America Corp DE Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS

September 20, 2026 | marketbeat.com

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks

September 19, 2026 | marketbeat.com

Engineers Gate Manager LP Sells 118,987 Shares of Ionis Pharmaceuticals, Inc. $IONS

September 19, 2026 | marketbeat.com

Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?

September 18, 2026 | finance.yahoo.com

Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 16, 2026 | seekingalpha.com

Guggenheim Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

September 16, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK), Axsome Therapeutics (AXSM) and Ionis Pharmaceuticals (IONS)

September 15, 2026 | theglobeandmail.com

Why Ionis Pharmaceuticals, Inc.’s (IONS) Stock Is Down 5.02%

September 15, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AGIO, IMVT, IONS, and ALKS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$33.20 -0.99 (-2.89%)

As of 10:27 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes NASDAQ:ALKS

$41.76 -0.38 (-0.89%)

As of 10:27 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$34.15 -0.39 (-1.12%)

As of 10:27 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ionis Pharmaceuticals NASDAQ:IONS

$44.26 +0.33 (+0.75%)

As of 10:27 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, IMVT, IONS, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, IMVT, IONS, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, IMVT, IONS, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, IMVT, IONS, and ALKS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, IMVT, IONS, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, IMVT, IONS, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, IMVT, IONS, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, IMVT, IONS, and ALKS Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools